Word

EMENDOBIO

Status

Pending

Status Code

774

Status Date

Monday, June 26, 2023

Serial Number

90798006

Mark Type

4000

Filing Date

Monday, June 28, 2021

Published for Opposition

Tuesday, December 27, 2022

Trademark Owner History

EmendoBio Inc. - Owner At Publication

Classifications

5 Enzyme preparations for medical purposes; enzymes for medical purposes; nucleases and nuclease panels for medical purposes; reagents for use in medical genetic testing; preparations for detecting genetic predispositions for medical purposes; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the prevention of diseases or decisions caused by genetic predispositions; pharmaceutical preparations for editing of faulty genes; chemical preparations for pharmaceutical or medical purposes, namely, for editing of faulty genes; anti-cancer preparations; pharmaceutical products for the prevention and treatment of cancer; ocular pharmaceuticals; pharmaceutical preparations and substances for the treatment of genetic blood disorders

1 Enzymes for scientific and research purposes; nucleases and nuclease panels for scientific and research purposes; nucleases and nuclease panels derived from biotechnological processes for use in scientific and research purposes; assays and reagents for use in genetic research; nucleases and nuclease panels for use in genetic research

42 Testing, research, or development of pharmaceutical preparations for gene therapy; testing, research, selection, optimization or development of nucleases for gene targeting, gene editing, or gene therapy; DNA analysis services for scientific research purposes; genetic testing for scientific research purposes; scientific research in the field of genetics, gene editing and genetic engineering; providing medical and scientific research information in the fields of pharmaceuticals and genetics; scientific research consulting in the field of genetics; scientific research consulting in the field of gene editing; scientific research consulting in the field of selection and optimization of nucleases for gene editing and pharmaceutical development; scientific research in the field of selection and optimization of nucleases for gene editing and pharmaceutical development; pharmaceutical research services, excluding production technologies; pharmaceutical research and development, excluding production technologies; pharmaceutical products development; pharmaceutical product evaluation; pharmaceutical drug development services, excluding production technologies; development of pharmaceutical preparations and medicines; technical research in the field of pharmaceutical studies, excluding production technologies; research and development in the pharmaceutical and biotechnology fields, excluding production technologies; testing of pharmaceuticals; laboratory research services relating to pharmaceuticals; conducting early evaluations in the field of new pharmaceuticals; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical research services in the field of cancer; medical research services in the field of genetic blood disorders; medical research services in the field of genetic ocular disorders; medical and scientific research in the field of cancer treatment and diagnosis; scientific research for medical purposes in the field of gene editing and genetic disorders; scientific research for medical purposes in the field of nuclease and nuclease panel discovery and optimization for the development of gene-targeting pharmaceuticals

Trademark Events

Jun 26, 2023

Opposition Instituted No. 999999

Jan 24, 2023

Extension Of Time To Oppose Received

Dec 27, 2022

Official Gazette Publication Confirmation E-Mailed

Dec 27, 2022

Published For Opposition

Dec 7, 2022

Notification Of Notice Of Publication E-Mailed

Nov 22, 2022

Approved For Pub - Principal Register

Nov 3, 2022

Teas/Email Correspondence Entered

Nov 3, 2022

Correspondence Received In Law Office

Nov 3, 2022

Teas Response To Office Action Received

May 3, 2022

Notification Of Non-Final Action E-Mailed

May 3, 2022

Non-Final Action E-Mailed

May 3, 2022

Non-Final Action Written

Mar 18, 2022

Assigned To Examiner

Sep 10, 2021

New Application Office Supplied Data Entered

Jul 1, 2021

New Application Entered